Inovio Pharmaceuticals (NASDAQ:INO) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a hold rating to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.

A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Thursday. Piper Sandler reissued an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and upped their price target for the company from $1.80 to $3.00 in a research note on Thursday. Weiss Ratings raised shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, June 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $3.17.

Inovio Pharmaceuticals Stock Up 16.9%

Shares of NASDAQ:INO opened at $0.90 on Wednesday. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98. The stock has a market cap of $74.05 million, a PE ratio of -0.99 and a beta of 1.52. The business has a 50 day moving average of $1.03 and a 200-day moving average of $1.30.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Equities research analysts expect that Inovio Pharmaceuticals will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $33,000. Raymond James Financial Inc. boosted its holdings in shares of Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares in the last quarter. GSA Capital Partners LLP raised its holdings in shares of Inovio Pharmaceuticals by 3.8% during the 4th quarter. GSA Capital Partners LLP now owns 459,828 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 16,724 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth $41,000. Institutional investors own 26.79% of the company’s stock.

Key Headlines Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: INO-3107 regulatory progress: The FDA’s review of Inovio’s biologics license application for recurrent respiratory papillomatosis is advancing toward an October 30, 2026 PDUFA decision date. The company is also preparing commercially for a potential launch, an important catalyst for the development-stage biotech. INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Smaller-than-expected loss: Inovio reported a second-quarter loss of $0.07 per share, substantially better than the $0.22 loss analysts expected. The narrower loss supports the near-term investment case, although the company remains unprofitable. Inovio Second-Quarter Earnings Results
• Positive Sentiment: Improved funding visibility: Management said its cash, cash equivalents, and short-term investments are expected to fund operations through late first quarter 2027, potentially covering the period through an INO-3107 launch if approved and reducing immediate financing pressure. Inovio Q2 2026 Earnings Call Highlights
• Positive Sentiment: Pipeline developments: Partner ApolloBio reported positive topline Phase 3 results for VGX-3100 in cervical dysplasia, while Inovio also highlighted progress in its DNA-encoded antibody and protein programs. Inovio Second-Quarter 2026 Financial Results
• Negative Sentiment: Key risks remain: INO-3107 still requires FDA approval, and the company continues to report losses. Any regulatory delay, rejection, weaker launch prospects, or future need for additional capital could pressure INO. Inovio Q2 2026 Earnings Call Transcript

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.